Heart failure & cardiomyopathies
Left ventricular mass as a modulator of ventricular arrhythmia risk and sex differences after cardiac resynchronization therapy (CRT) for nonischemic cardiomyopathy and LBBB
Main findingResult — go to the resultHazard ratio 1.01 95% CI 1.001–1.009Authors' conclusion
VA risk after CRT implantation in nonischemic cardiomyopathy was associated with baseline LV > 308.9 g and a decrease in LVM ≤ 20%, without sex differences.
Study context
- Population
- Patients with nonischemic cardiomyopathy and LBBB undergoing CRT implantation
- Participants
- 118 patients
- Exposure
- Baseline left ventricular mass (LVM) and post-implant change in LVM, and sex, as predictors of VA after CRT
- Malen = 47
- Femalen = 71reference
- Outcome
- VA events (appropriate shocks or antitachycardia pacing) from device diagnostics and therapies
- Follow-up
- Median 90 months (IQR 44-158)
Main finding
As reported in the abstract
Hazard ratio
1.01
95% CI 1.001–1.009
P = 0.003
Events by group
- Any VA (appropriate shocks or ATP), all patients
- 35 (29.6%)
- Baseline LVM > 308.9 g separated patients with higher VA risk
- P = 0.001
- <20% decrease in LVM increased VA risk
- P < 0.001
Observational data: associations, not effects.
Original publication
Left ventricular mass as a modulator of ventricular arrhythmia risk and sex differences after CRT for nonischemic cardiomyopathy and LBBB. Heart Rhythm. Published 29 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →